Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-10

Clinical Trial Update: A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update of a single ProHema CB product for pediatric hematologic malignancies; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ProHema CB

Snippet

Sponsor: Fate Therapeutics | Conditions: Hematologic Malignancies | Phase 1 | Status: TERMINATED | Results posted: 2018-10-10